Please login to the form below

Not currently logged in
Email:
Password:

EUSA Pharma to acquire Cytogen

European based EUSA Pharma announced on March 11 that it has entered into an agreement to buy the remaining shares of Cytogen Corporation for $22.6m.

European based EUSA Pharma announced on March 11 that it has entered into an agreement to buy the remaining shares of Cytogen Corporation for $22.6m.

Cytogen, located in the US, made a net loss last year of $25.7m and the acquisition by EUSA Pharma will see shareholders receive $0.62 per share, with the company currently holding a value of $22.6m.

In a move that will expand the company's transatlantic infrastructure, EUSA, which was founded in the UK, will be able to use this strategic growth platform to exploit additional products and operate alongside major industry competitors.

Rolf Stahel, chairman of EUSA, said: "This transaction will transform our business, putting in place a truly transatlantic growth platform, and positioning the company as the partner of choice for future acquisitions and speciality product in-licensing."

EUSA specialises in the fields of critical care and oncology and currently has 6 products on the EU market, some of which can be used for the treatment of lymphoblastic leukaemia.

In addition to a dedicated US sales force and commercial framework, Cytogen currently has three oncology and pain control products on the American Market.

Bryan Morton, CEO of EUSA, said: "Cytogen's products and US infrastructure are the ideal complement to our business, offering us the opportunity to commercialise a rapidly growing portfolio of medicines on both sides of the Atlantic."

11th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics